Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: real-world efficacy and risks of early ponatinib dose reduction.
Not available.
APA
Yoon JH, Min KI, et al. (2026). Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: real-world efficacy and risks of early ponatinib dose reduction.. Haematologica. https://doi.org/10.3324/haematol.2025.300099
MLA
Yoon JH, et al.. "Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: real-world efficacy and risks of early ponatinib dose reduction.." Haematologica, 2026.
PMID
41609055
Abstract
Not available.
같은 제1저자의 인용 많은 논문 (5)
- Real-world outcomes of inotuzumab ozogamicin treatment for adult relapsed or refractory acute lymphoblastic leukemia: a result from Korea post-marketing surveillance.
- Diagnostic Performance and Clinical Implications of the "Probable Hepatocellular Carcinoma" Category in the Korean Liver Cancer Association-National Cancer Center Korea Guidelines v2022.
- Commercially Available Artificial Intelligence Score on Preoperative Mammography for Prediction of Future Breast Cancer After DCIS Treatment.
- Evaluation of the performance of radiologists assisted by AI in detecting colorectal liver metastases on contrast-enhanced CT.
- Comparison of Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging and Contrast-Enhanced Computed Tomography for the Noninvasive Diagnosis of Hepatocellular Carcinoma.